LAUSR

In this issue of HEPATOLOGY, Fredrik Åberg and co-authors put an end to the ongoing debate whether moderate alcohol drinking (less than 20 g of alcohol/day or 2 drinks per day) could be helpful for the health of subjects with nonalcoholic fatty liver disease (NAFLD) and, therefore, if patients with NAFLD may be allowed to drink not more than 2 drinks per day. NAFLD is booming worldwide, together with the increasing prevalence of type2 diabetes mellitus (T2DM), obesity, and metabolic syndrome. NAFLD is now the most common liver disorder in Western countries and affects as many as 25%-30% of adults, and NAFLD might shortly become the most common liver disease worldwide. Cardiovascular disease (CVD) and not liver disease is the leading cause of death among patients with NAFLD. Moderate drinking (vs. abstinence) has been associated with a lower risk of CVD in the general population. This conclusion has been challenged in a more recent study where moderate consumption of alcohol did not reduce the risk of CVD in patients with NAFLD. Therefore, this practical issue is not yet completely clarified. Which is the answer that the hepatologist and the General Practioner should give a patient with NAFLD asking: “Doctor, can I keep on drinking a couple of glasses of wine every day?” The current assumption is that low or moderate alcohol consumption should be forbidden in patients with chronic liver disease (CLD). Therefore, subjects with CLD, regardless of its etiology, are usually warned to avoid any kind of alcoholic beverage. An answer as to whether moderate drinking (1 to 2 drinks per day) is safe in patients with NAFLD can be found from what is described by Åberg et al. They followed up 6,771 (84%) of the 8,028 Finnish persons that had been enrolled in the Finnish Population Health 2000 Study. Through a two-stage stratified procedure, the Finnish Population Health Study was intended to be representative of the entire Finnish population. Hospitalization data were obtained from the National Hospital Discharge Register, cancer data from the Finnish Cancer Registry, and the cause of death from the Statistics Finland database. This is an ideal research setting for evaluating the burden of liver or any disease because it starts with a general population and links events occurring later in life using reliable sources about disease and death. Åberg et al. are to be congratulated for contributing to our knowledge about the burden of liver disease in the general population. After a mean (SD) follow-up time of 11 years, there were 84 liver-related outcomes, that is, 60 hospitalizations for liver disease, nine primary liver cancers, and 15 liver-related deaths corresponding to an incidence rate of 1.2%. When only hospitalizations for liver disease and liver-related deaths were considered (n 5 75), 47 occurred in the 5,224 men drinking less than 30 g/day of ethanol or women drinking less than 20 g/day of ethanol, yielding an incidence rate of 0.9%. Among the 710 men drinking more than 30 g/day of ethanol or women drinking more than 20 g/day of ethanol, the corresponding number was 47, yielding an incidence rate of 3.9%. These numbers tell that although incident liver disease was more common among heavy drinkers, it was present also among nonheavy drinkers as defined by current guidelines. The Abbreviations: BMI, body mass index; CLD, chronic liver disease; CVD, cardiovascular disease; LDL, low-density lipoprotein; NAFLD, nonalcoholic fatty liver disease; T2DM, type2 diabetes mellitus; WC, waist circumference.